Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (1543)	2/6/2002 8:25:14 AM
From: Robohogs	Read Replies (1) \| Respond to of 10345

But given what has happened here, one cannot trust any of the numbers. Hence, that cash number is negative if one ignores offbalance sheet treatment of the SPEs. You then have negative cash (net of debt) of $600 million. In this environment, that is what people are focused on, and I don't blame them. Oh yeah, the $400 million of sales that come from the two drugs with generic sales imminent could be $200 million soon. The portfolio of products here is not worth 10x. The value here is the stock in biotechs, the early stage compounds in the jvs, the drug delivery technology and Antegren, as well as all of the Alzheimers product candidates (not counting the failed one). Do I think that is all worth $30? Yes Do I think the market will value it there? no Do I trust management? NFW Should one invest in any company with questionable management and ethics? NFW PS I still haven't sold what is now my 6th largest position (down from 3rd). Jon